Primary pulmonary hypertension

Lancet

Volumn 361, Issue 9368, 2003, Pages 1533-1544

  Runo, James R ^a   Loyd, James E ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ARGININE; BERAPROST; BONE MORPHOGENETIC PROTEIN RECEPTOR; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CARBAMOYL PHOSPHATE SYNTHASE; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; PHOSPHODIESTERASE INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTACYCLIN; RECEPTOR SUBUNIT; SEROTONIN; SILDENAFIL; STATIN; UNIPROST; VOLTAGE GATED POTASSIUM CHANNEL;

CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; COUGHING; DIAGNOSTIC PROCEDURE; DIARRHEA; DISEASE PREDISPOSITION; DRUG HALF LIFE; DRUG INFUSION; DRUG WITHDRAWAL; DYSPNEA; ECHOCARDIOGRAPHY; ENDOTHELIUM LESION; EXTRACELLULAR MATRIX; FIBRINOLYSIS; FLUSHING; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; GENETIC CODE; HEADACHE; HEART RIGHT VENTRICLE FAILURE; HEMODYNAMICS; HEREDITARY HYPERTENSION; HUMAN; JAW; LIVER DYSFUNCTION; LUNG TRANSPLANTATION; NAUSEA; NONHUMAN; PAIN; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK FACTOR; SCREENING; SIDE EFFECT; SURGICAL TECHNIQUE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0037623284     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)13167-4     Document Type: Conference Paper

References (156)

1. Rich S., Dantzker D.R., Ayres S.M., et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med. 107:1987;216-223.
2. D'Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med. 115:1991;343-349.
3. Fuster V., Steele P.M., Edwards W.D., Gersh B.J., McGoon M.D., Frye R.L. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 70:1984;580-587.
4. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension. Nat Genet. 26:2000;81-84.
5. Deng Z., Morse J.H., Slager S.L., et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet. 67:2000;737-744.
6. Dresdale D.T., Schultz M., Michtom R.J. Primary pulmonary hypertension - I: clinical and hemodynamic study. Am J Med. 11:1951;686-701.
7. Dresdale D.T., Michtom R.J., Schultz M. Recent studies in primary pulmonary hypertension, including pharmacodynamic observations on pulmonary vascular resistance. Bull NY Acad Med. 30:1954;195-207.
8. Gaine S.P., Rubin L.J. Primary pulmonary hypertension. Lancet. 352:1998;719-725.
9. Rich SE. Executive summary from the World Symposium on Primary Pulmonary Hypertension 1998. http://www.who.int/ned/cvd/pph.html (accessed April 2, 2003).
10. Loyd J.E., Butler M.G., Foroud T.M., Conneally P.M., Phillips J.A., Newman J.H. Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am J Respir Crit Care Med. 152:1995;93-97.
11. Loyd J.E., Primm R.K., Newman J.H. Familial primary pulmonary hypertension: clinical patterns. Am Rev Respir Dis. 129:1984;194-197.
12. Newman J.H., Wheeler L., Lane K.B., et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med. 345:2001;319-324.
13. Elliott G., Alexander G., Leppert M., Yeates S., Kerber R. Coancestry in apparently sporadic primary pulmonary hypertension. Chest. 108:1995;973-977.
14. Kay J.M., Smith P., Heath D. Aminorex and the pulmonary circulation. Thorax. 26:1971;262-270.
15. Abenhaim L., Moride Y., Brenot F., et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med. 335:1996;609-616.
16. Mark E.J., Patalas E.D., Chang H.T., Evans R.J., Kessler S.C. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. N Engl J Med. 337:1997;602-606.
17. Garcia-Dorado D., Miller D.D., Garcia E.J., Delcan J., Maroto E., Chaitman B.R. An epidemic of pulmonary hypertension after toxic rapeseed oil ingestion in Spain. J Am Coll Cardiol. 1:1983;1216-1222.
18. Opravil M., Pechere M., Speich R., et al. HIV-associated primary pulmonary hypertension: a case control study. Am J Respir Crit Care Med. 155:1997;990-995.
19. Hervé P., Lebrec D., Brenot F., et al. Pulmonary vascular disorders in portal hypertension. Eur Respir J. 11:1998;1153-1166.
20. Morse J.H., Horn E.M., Barst R.J. Hormone replacement therapy: a possible risk factor in carriers of familial primary pulmonary hypertension. Chest. 116:1999;847.
21. Wagenvoort C.A. Lung biopsy specimens in the evaluation of pulmonary vascular disease. Chest. 77:1980;614-625.
22. Bjornsson J., Edwards W.D. Primary pulmonary hypertension: a histopathologic study of 80 cases. Mayo Clin Proc. 60:1985;16-25.
23. Pietra G.G., Edwards W.D., Kay J.M., et al. Histopathology of primary pulmonary hypertension: a qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute primary pulmonary hypertension registry. Circulation. 80:1989;1198-1206.
24. Loyd J.E., Atkinson J.B., Pietra G.G., Virmani R., Newman J.H. Heterogeneity of pathologic lesions in familial primary pulmonary hypertension. Am Rev Respir Dis. 138:1988;952-957.
25. Smith P., Heath D., Yacoub M.H., Madden B., Caslin A., Gosney J. The ultrastructure of plexogenic pulmonary arteriopathy. J Pathol. 160:1990;111-121.
26. Cool C.D., Kennedy D., Voelkel N.F., Tuder R.M. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol. 28:1997;434-442.
27. Yi E.S., Kim H., Ahn H., et al. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension: a morphometric and immunohistochemical study. Am J Respir Crit Care Med. 162:2000;1577-1586.
28. Tuder R.M., Groves B., Badesch D.B., Voelkel N.F. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol. 144:1994;275-285.
29. Lee S., Shroyer K.R., Markham N.E., Cool C.D., Voelkel N.F., Tuder R.M. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest. 101:1998;927-934.
30. Yeager M.E., Halley G.R., Golpon H.A., Voelkel N.F., Tuder R.M. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ Res. 88:2001;e2-e11.
31. Thomson J.R., Machado R.D., Pauciulo M.W., et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family. J Med Genet. 37:2000;741-745.
32. Machado R.D., Pauciulo M.W., Thomson J.R., et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet. 68:2001;92-102.
33. Deng Z., Haghighi F., Helleby L., et al. Fine mapping of PPH1, a gene for familial primary pulmonary hypertension, to a 3-cM region on chromosome 2q33. Am J Respir Crit Care Med. 161:2000;1055-1059.
34. Cummings C.J., Zoghbi H.Y. Fourteen and counting: unraveling trinucleotide repeat diseases. Hum Mol Genet. 9:2000;909-916.
35. Heldin C., Miyazono K., ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature. 390:1997;465-471.
36. Blobe G.C., Schiemann W.P., Lodish H.F. Role of transforming growth factor β in human disease. N Engl J Med. 342:2000;1350-1358.
37. Hogan B.L.M. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev. 10:1996;1580-1594.
38. Rudarakanchana N., Flanagan J.A., Chen H., et al. Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. Hum Mol Genet. 11:2002;1517-1525.
39. Nishihara A., Watabe T., Imamura T., Miyazono K. Functional heterogeneity of bone morphogenetic protein receptor-II mutants found in patients with primary pulmonary hypertension. Mol Biol Cell. 13:2002;3055-3063.
40. Atkinson C., Stewart S., Upton P.D., et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation. 105:2002;1672-1678.
41. Dorai H., Vukicevic S., Sampath T.K. Bone morphogenetic protein-7 (osteogenic protein-1) inhibits smooth muscle cell proliferation and stimulates the expression of markers that are characteristic of SMC phenotype in vitro. J Cell Physiol. 184:2000;37-45.
42. Nakaoka T., Gonda K., Ogita T., et al. Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2. J Clin Invest. 100:1997;2824-2832.
43. Morrell N.W., Yang X., Upton P.D., et al. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-β1 and bone morphogenetic proteins. Circulation. 104:2001;790-795.
44. McCaffrey T.A., Du B., Consigli S., Szabo P., et al. Genomic instability in the type II TGF-beta 1 receptor gene in atherosclerotic and restenotic vascular cells. J Clin Invest. 100:1997;2182-2188.
45. Akiyama Y., Iwanaga R., Saitoh K., et al. Transforming growth factor beta type II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer. Gastroenterology. 112:1997;33-39.
46. McAllister K.A., Grogg K.M., Johnson D.W., et al. Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet. 8:1994;345-351.
47. Johnson D.W., Berg J.N., Baldwin M.A., et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet. 13:1996;189-195.
48. Trembath R.C., Thomson J.R., Machado R.D., et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med. 345:2001;325-334.
49. Rudarakanchana N., Trembath R.C., Morrell N.W. New insights into the pathogenesis and treatment of primary pulmonary hypertension. Thorax. 56:2001;888-890.
50. Christman B., McPherson C.D., Newman J.H., et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 327:1992;70-75.
51. Tuder R.M., Cool C.D., Geraci M.W., et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 159:1999;1925-1932.
52. Geraci M.W., Gao B., Shepherd D.C., et al. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest. 103:1999;1509-1515.
53. Nagaya N., Yokoyama C., Kyotani S., et al. Gene transfer of human prostacyclin synthase ameliorates monocrotaline-induced pulmonary hypertension in rats. Circulation. 102:2000;2005-2010.
54. Giaid A., Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 333:1995;214-221.
55. Giaid A., Yanagisawa M., Langleben D., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 328:1993;1732-1739.
56. Davie N., Haleen S.J., Upton P.D., et al. ETA and ETB receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med. 165:2002;398-405.
57. Hoeper M.M., Voelkel N.F., Bates T.O., et al. Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP. Am J Respir Cell Mol Biol. 17:1997;748-756.
58. Tuder R.M., Chacon M., Alger L., et al. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol. 195:2001;367-374.
59. Taraseviciene-Stewart L., Kasahara Y., Alger L., et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J. 15:2001;427-438.
60. Campbell A.I.M., Zhao Y., Sandhu R., Stewart D.J. Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension. Circulation. 104:2001;2242-2248.
61. Cowan K.N., Jones P.L., Rabinovitch M. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J Clin Invest. 105:2000;21-34.
62. Cowan K.N., Heilbut A., Humpl T., Lam C., Ito S., Rabinovitch M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med. 6:2000;698-702.
63. Mitani Y., Zaidi S.H.E., Dufourcq P., et al. Nitric oxide reduces vascular smooth muscle cell elastase activity through cGMP-mediated suppression of ERK phosphorylation and AM1B nuclear partitioning. FASEB J. 14:2000;805-814.
64. McGoon M.D., Vanhoutte P.M. Aggregating platelets contract isolated canine pulmonary arteries by releasing 5-hydroxytryptamine. J Clin Invest. 74:1984;828-833.
65. MacLean M.R., Herve P., Eddahibi S., Adnot S. 5-hydroxytryptamine and the pulmonary circulation.,@ Receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol. 131:2000;161-168.
66. Lee S.L., Wang W.W., Moore B.J., Fanburg B.L. Dual effect of serotonin on growth of bovine pulmonary artery smooth muscle cell in culture. Circ Res. 68:1991;1362-1368.
67. Hervé P., Drouet L., Dosquet C., et al. Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: role of serotonin. Am J Med. 89:1990;117-120.
68. Hervé P., Launay J., Scrobohaci M., et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med. 99:1995;249-254.
69. Kereveur A., Callebert J., Humbert M., et al. High plasma serotonin levels in primary pulmonary hypertension: effect of long-term epoprostenol (prostacyclin) therapy. Arterioscler Thromb Vasc Biol. 20:2000;2233-2239.
70. Eddahibi S., Fabre V., Boni C., et al. Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells: relationship with the mitogenic action of serotonin. Circ Res. 84:1999;329-336.
71. Eddahibi S., Hanoun N., Lanfumey L., et al. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest. 105:2000;1555-1562.
72. Eddahibi S., Humbert M., Fadel E., et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest. 108:2001;1141-1150.
73. Rothman R.B., Ayestas M.A., Dersch C.M., Baumann M.H. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates: implications for primary pulmonary hypertension. Circulation. 100:1999;869-875.
74. + channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation. 98:1998;1400-1406.
75. + channel gene transcription in primary pulmonary hypertension. Lancet. 351:1998;726-727.
76. Weir E.K., Reeve H.L., Huang J.M.C., et al. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation. 94:1996;2216-2220.
77. Orte C., Polak J.M., Haworth S.G., Yacoub M.H., Morrell N.W. Expression of pulmonary vascular angiotensin-converting enzyme in primary and secondary plexiform pulmonary hypertension. J Pathol. 192:2000;379-384.
78. Schuster D.P., Crouch E.C., Parks W.C., Johnson T., Botney M.D. Angiotensin converting enzyme expression in primary pulmonary hypertension. Am J Respir Crit Care Med. 154:1996;1087-1091.
79. Morrell N.W., Upton P.D., Kotecha S., et al. Angiotensin II activates MAPK and stimulates growth of human pulmonary artery smooth muscle via AT1 receptors. Am J Physiol. 277:1999;L440-L448.
80. Okada K., Bernstein M.L., Zhang W., Schuster D.P., Botney M.D. Angiotensin-converting enzyme inhibition delays pulmonary vascular neointimal formation. Am J Respir Crit Care Med. 158:1998;939-950.
81. Benza RL. Association of a gene polymorphism for PAI-1 with primary pulmonary hypertension. Cardiopulm Crit Care Newsletter 2002; Spring: 7-9.
82. Inglesby T.V., Singer J.W., Gordon D.S. Abnormal fibrinolysis in familial pulmonary hypertension. Am J Med. 55:1973;5-13.
83. Rich S., Hart K. Familial pulmonary hypertension in association with an abnormal hemoglobin: insights into the pathogenesis of primary pulmonary hypertension. Chest. 99:1991;1208-1210.
84. Huber K., Beckmann R., Frank H., Kneussl M., Mlczoch J., Binder B.R. Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension. Am J Respir Crit Care Med. 150:1994;929-933.
85. Pearson D.L., Dawling S., Walsh W.F., et al. Neonatal pulmonary hypertension: urea-cycle intermediates, nitric oxide production, and carbamoyl-phosphate synthetase function. N Engl J Med. 344:2001;1832-1838.
86. Rich S., Pietra G.G., Kieras K., Hart K., Brundage B.H. Primary pulmonary hypertension: radiographic and scintigraphic patterns of histologic subtypes. Ann Intern Med. 105:1986;499-502.
87. D'Alonzo G.E., Bower J.S., Dantzker D.R. Differentiation of patients with primary and thromboembolic pulmonary hypertension. Chest. 85:1984;457-461.
88. Nicod P., Peterson K., Levine M., et al. Pulmonary angiography in severe chronic pulmonary hypertension. Ann Intern Med. 107:1987;565-568.
89. D'Alonzo G.E., Gianotti L.A., Pohil R.L., et al. Comparison of progressive exercise performance of normal subjects and patients with primary pulmonary hypertension. Chest. 92:1987;57-62.
90. Miyamoto S., Nagaya N., Satoh T., et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardio-pulmonary exercise testing. Am J Respir Crit Care Med. 161:2000;487-492.
91. Weir E.K., Rubin L.J., Ayres S.M., et al. The acute administration of vasodilators in primary pulmonary hypertension: experience from the National Institutes of Health registry on primary pulmonary hypertension. Am Rev Respir Dis. 140:1989;1623-1630.
92. Sandoval J., Bauerle O., Palomar A., et al. Survival in primary pulmonary hypertension: validation of a prognostic equation. Circulation. 89:1994;1733-1744.
93. Rich S., Kaufmann E., Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 327:1992;76-81.
94. Rich S., Brundage B.H. High-dose calcium channel-blocking therapy for primary pulmonary hypertension. Evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation. 76:1987;135-141.
95. Vane J.R., Botting R.M. Pharmacodynamic profile of prostacyclin. Am J Cardiol. 75:1995;3A-10A.
96. Higenbottam T.W., Spiegelhalter D., Scott J.P., et al. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br Heart J. 70:1993;366-370.
97. Barst R.J., Rubin L.J., McGoon M.D., Caldwell E.J., Long W.A., Levy P.S. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann lntern Med. 121:1994;409-415.
98. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 334:1996;296-301.
99. Badesch D.B., Tapson V.F., McGoon M.D., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Ann Intern Med. 132:2000;425-434.
100. Robbins I.M., Gaine S.P., Schilz R., Tapson V.F., Rubin L.J., Loyd J.E. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest. 117:2000;14-18.
101. Rosenzweig E.B., Kerstein D., Barst R.J. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation. 99:1999;1858-1865.
102. Aguilar R.V., Farber H.W. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med. 162:2000;1846-1850.
103. McLaughlin V.V., Genthner D.E., Panella M.M., Hess D.M., Rich S. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med. 130:1999;740-743.
104. McLaughlin V.V., Genthner D.E., Panella M.M., Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med. 338:1998;273-277.
105. Palmer S.M., Robinson L.J., Wang A., Gossage J.R., Bashore T., Tapson V.F. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest. 113:1998;237-240.
106. Friedman R., Mears J.G., Barst R.J. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation. 96:1997;2782-2784.
107. Langleben D., Barst R.J., Badesch D.B., et al. Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension. Circulation. 99:1999;3266-3271.
108. Eddahibi S., Humbert M., Sediame S., et al. Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension: effect of prostacyclin therapy. Am J Respir Crit Care Med. 162:2000;1493-1499.
109. Clapp L.H., Finney P., Turcato S., Tran S., Rubin L.J., Tinker A. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol. 26:2002;194-201.
110. Castelain V., Chemla D., Humbert M., et al. Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension. Am J Respir Crit Care Med. 165:2002;338-340.
111. Reitz B.A., Wallwork J.L., Hunt S.A., et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med. 306:1982;557-564.
112. International guidelines for the selection of lung transplant candidates. Am J Respir Crit Care Med 1998; 158: 335-39.
113. Pasque M.K., Trulock E.P., Cooper J.D., et al. Single lung transplantation for pulmonary hypertension: single institution experience in 34 patients. Circulation. 92:1995;2252-2258.
114. Gammie J.S., Keenan R.J., Pham S.M., et al. Single-versus double-lung transplantation for pulmonary hypertension. J Thorac Cardiovasc Surg. 115:1998;397-403.
115. Bando K., Armitage J.M., Paradis I.L., et al. Indications for and results of single, bilateral, and heart-lung transplantation for pulmonary hypertension. J Thorac Cardiovasc Surg. 108:1994;1056-1065.
116. Levine S.M., Jenkinson S.G., Bryan C.L., et al. Ventilation-perfusion inequalities during graft rejection in patients undergoing single lung transplantation for primary pulmonary hypertension. Chest. 101:1992;401-405.
117. Kshettry V.R., Kroshus T.J., Savik K., Hertz M.I., Bolman R.M. I.I.I. Primary pulmonary hypertension as a risk factor for the development of obliterative bronchiolitis in lung allograft recipients. Chest. 110:1996;704-709.
118. Rozkovec A., Montanes P., Oakley C.M. Factors that influence the outcome of primary pulmonary hypertension. Br Heart J. 55:1986;449-458.
119. Rich S., Dodin E., McLaughlin V.V. Usefulness of atrial septostomy as a treatment for primary pulmonary hypertension and guidelines for its application. Am J Cardiol. 80:1997;369-371.
120. Sandoval J., Gaspar J., Pulido T., et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension: a therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol. 32:1998;297-304.
121. Rothman A., Beltran D., Kriett J.M., Smith C., Wolf P., Jamieson S.W. Graded balloon dilation atrial septostomy as a bridge to lung transplantation in pulmonary hypertension. Am Heart J. 125:1993;1763-1766.
122. Saji T., Ozawa Y., Ishikita T., Matsuura H., Matsuo N. Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension. Am J Cardiol. 78:1996;244-247.
123. Ichida F., Uese K., Tsubata S., et al. Additive effect of beraprost on pulmonary vasodilation by inhaled nitric oxide in children with pulmonary hypertension. Am J Cardiol. 80:1997;662-664.
124. Nagaya N., Uematsu M., Okano Y., et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol. 34:1999;1188-1192.
125. Galie N., Humbert M., Vachiéry J., et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 39:2002;1496-1502.
126. Hoeper M.M., Olschewski H., Ghofrani H.A., et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. J Am Coll Cardiol. 35:1999;176-182.
127. Blumberg F.C., Riegger G.A.J., Pfeifer M. Hemodynamic effects of aerosolized iloprost in pulmonary hypertension at rest and during exercise. Chest. 121:2002;1566-1571.
128. Olschewski H., Ghofrani H.A., Schmehl T., et al. Inhaled iloprost to treat severe pulmonary hypertension: an uncontrolled trial. Ann Intern Med. 132:2000;435-443.
129. Olschewski H., Ghofrani H.A., Walmrath D., Grimminger F., Seeger W. Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost. Intensive Care Med. 24:1998;631-634.
130. Hoeper M.M., Schwarze M., Ehlerding S., et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 342:2000;1866-1870.
131. Olschewski H., Simonneau G., Galie N., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 347:2002;322-329.
132. Simonneau G., Barst R.J., Galie N., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 165:2002;800-804.
133. Hamilton G., Saba T., Corris P., et al. Improvement of exercise tolerance due to uniprost in patients with pulmonary arterial hypertension is related to baseline performance. Am J Respir Crit Care Med. 163:2001;A540. abstr.
134. Vachiéry J., Hill N., Zwicke D., Barst R.J., Blackburn S., Naeije R. Transitioning from iv epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest. 121:2002;1561-1565.
135. Hoeper M.M., Galie N., Simonneau G., Rubin L.J. New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med. 165:2002;1209-1216.
136. Galie N., Grigioni F., Bacchi-Reggiani L., et al. Relation of endothelin-1 to survival in patients with primary pulmonary hypertension. Eur J Clin Invest. 26:1996;A48.
137. Channick R.N., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 358:2001;1119-1123.
138. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 346:2002;896-903.
139. Channick R.N., Rubin L.J. Endothelin receptor antagonism: a new era in the treatment of pulmonary arterial hypertension. Pulm Hypertens. 1:2002;13-17.
140. Barst R.J., Rich S., Widlitz A., Horn E.M., McLaughlin V.V., McFarlin J. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest. 121:2002;1860-1868.
141. Bogdan M., Humbert M., Francoual J., et al. Urinary cGMP concentrations in severe primary pulmonary hypertension. Thorax. 53:1998;1059-1062.
142. Zhao L., Mason N.A., Morrell N.W., et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation. 104:2001;424-428.
143. Shekerdemian L.S., Ravn H.B., Penny D.J. Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am J Respir Crit Care Med. 165:2002;1098-1102.
144. Prasad S., Wilkinson J., Gatzoulis M.A. Sildenafil in primary pulmonary hypertension. N Engl J Med. 343:2000;1342.
145. Schumacher Y.O., Zdebik A., Huonker M., Kreisel W. Sildenafil in HIV-related pulmonary hypertension. AIDS. 15:2001;1747-1748.
146. Ghofrani H.A., Wiedemann R., Rose F., et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med. 136:2002;515-522.
147. Nagaya N., Uematsu M., Oya H., et al. Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. Am J Respir Crit Care Med. 163:2001;887-891.
148. Mehta S., Stewart D.J., Langleben D., Levy R.D. Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension. Circulation. 92:1995;1539-1545.
149. Baudouin S.V., Bath P., Martin J.F., Du Bois R., Evans T.W. L-arginine infusion has no effect on systemic haemodynamics in normal volunteers, or systemic and pulmonary haemodynamics in patients with elevated pulmonary vascular resistance. Br J Clin Pharmacol. 36:1993;45-49.
150. Boger R.H., Mugge A., Bode-Boger S.M., Heinzel D., Höper M.M., Frolich J.C. Differential systemic and pulmonary hemodynamic effects of L-arginine in patients with coronary artery disease or primary pulmonary hypertension. Int J Clin Pharmacol Ther. 34:1996;323-328.
151. Mitani Y., Maruyama K., Sakurai M. Prolonged administration of L-arginine ameliorates chronic pulmonary hypertension and pulmonary vascular remodeling in rats. Circulation. 96:1997;689-697.
152. Laufs U., La Fata V., Liao J.K. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem. 272:1997;31725-31729.
153. Laufs U., Marra D., Node K., Liao J.K. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27 (Kip 1). J Biol Chem. 274:1999;21926-21931.
154. Indolfi C., Cioppa A., Stabile E., et al. Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointima1 formation in vivo after vascular injury. J Am Coll Cardiol. 35:2000;214-221.
155. Girgis R.E., Li D., Tuder R.M., Johns R.A., Garcia J.G.N. Attenuation of hypoxic pulmonary hypertension in rats by the HMG-CoA reductase inhibitor simvastatin. J Heart Lung Transplant. 21:2002;149.
156. Grünig E., Janssen B., Mereles D., et al. Abnormal pulmonary artery pressure response in asymptomatic carriers of primary pulmonary hypertension gene. Circulation. 102:2000;1145-1150.